CompanyGraph
J.B. Chemicals & Pharmaceuticals Ltd.
JBCHEPHARM · NSE India · India
jbpharma.comFinancials as of FY2026
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $4.05B, above the global median of $1.15B
- FinancialsHigh earnings quality
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.77%Below 5Y avg (0.80%)
Annual Rate
INR 18.60Paid semi-annual
Payout Ratio
44.3%Sustainable
Last Ex-Dividend
May 29, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
386.77BINR4.05B · vs all stocks (USD)
Trailing P/E
54.22xRevenue (TTM)
41.48BINR434.69M · vs all stocks (USD)
Profit Margin
17.11%Beta
-0.0180xvs all stocks
52-Week Change
42.98%vs all stocks
Forward Annual Dividend Yield
0.77%vs all stocks
Market Capitalization
386.77BINR4.05B · vs all stocks (USD)
Enterprise Value
374.59BINR3.93B · vs all stocks (USD)
Trailing P/E
54.22xForward P/E
33.16xPrice to Sales (TTM)
9.35xPrice to Book (MRQ)
9.33xEnterprise to Revenue
9.03xEnterprise to EBITDA
34.34xGross Margin
69.67%Profit Margin
17.11%Operating Margin
16.48%Return on Assets (TTM)
12.48%Return on Equity (TTM)
18.69%Revenue (TTM)
41.48BINR434.69M · vs all stocks (USD)
Revenue per Share (TTM)
264.00INRUpdated Jul 20, 2026Quarterly Revenue Growth
-4.80%Gross Profit (TTM)
28.11BINR294.58M · vs all stocks (USD)
EBITDA (TTM)
11.68BINR122.36M · vs all stocks (USD)
Net Income (TTM)
7.09BINR74.35M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-30.40%Operating Cash Flow (TTM)
7.04BINR73.77M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
5.06BINR53.08M · vs all stocks (USD)
Forward Annual Dividend Rate
18.60INRUpdated Jul 20, 2026Forward Annual Dividend Yield
0.77%vs all stocks
Trailing Annual Dividend Rate
22.00INRUpdated Jul 20, 2026Trailing Annual Dividend Yield
0.91%vs all stocks
5-Year Average Dividend Yield
0.80%vs all stocks
Payout Ratio
44.32%Minority Interest (Equity)
0.00INRFY2026 · Mar 31, 2026Revenue
40.76BINRFY2026 · Mar 31, 2026Cost of Goods Sold
13.24BINRFY2026 · Mar 31, 2026Gross Profit
27.52BINRFY2026 · Mar 31, 2026Operating Income
9.01BINR94.41M · vs all stocks (USD)
Pre-tax Income
9.52BINRFY2026 · Mar 31, 2026Income Tax Expense
2.43BINRFY2026 · Mar 31, 2026Net Income
7.09BINRFY2026 · Mar 31, 2026EBIT
9.58BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
11.41BINRFY2026 · Mar 31, 2026Selling, General & Administrative
5.08BINRFY2026 · Mar 31, 2026Other Operating Expenses
3.72BINRFY2026 · Mar 31, 2026Non-operating Interest Income
337.47MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
54.41MINRFY2026 · Mar 31, 2026Minority Interests (P&L)
0.00INRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
7.83BINRFY2026 · Mar 31, 2026Free Cash Flow
7.02BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
1.10BINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
9.52BINRFY2026 · Mar 31, 2026Stock-based Compensation
710.10MINRFY2026 · Mar 31, 2026Other Non-cash Items
-293.54MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-565.80MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-1.54BINRFY2026 · Mar 31, 2026Capital Expenditures
-813.33MINRFY2026 · Mar 31, 2026Net Intangibles (CF)
0.00INRFY2026 · Mar 31, 2026Purchase of Investments
-23.94BINRFY2026 · Mar 31, 2026Sale of Investments
18.79BINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-5.96BINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
-138.04MINRFY2026 · Mar 31, 2026Common Dividends Paid
-3.13BINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-951.37MINRFY2026 · Mar 31, 2026Shares Outstanding
160.56MSharesUpdated Jul 20, 2026Float Shares
81.52MSharesUpdated Jul 20, 2026% Held by Insiders
49.23%vs all stocks
% Held by Institutions
30.80%vs all stocks
Total Cash (MRQ)
12.21BINR128.00M · vs all stocks (USD)
Total Cash per Share (MRQ)
76.07INRUpdated Jul 20, 2026Total Debt (MRQ)
35.89MINR376.16K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0009xCurrent Ratio (MRQ)
4.92xBook Value per Share (MRQ)
259.05INRUpdated Jul 20, 2026Total Assets
49.69BINR520.71M · vs all stocks (USD)
Total Current Assets
29.09BINRFY2026 · Mar 31, 2026Total Liabilities
8.09BINRFY2026 · Mar 31, 2026Total Non-current Assets
20.59BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
2.18BINRFY2026 · Mar 31, 2026Total Current Liabilities
5.91BINRFY2026 · Mar 31, 2026Cash
1.07BINRFY2026 · Mar 31, 2026Cash Equivalents
28.80MINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
1.10BINRFY2026 · Mar 31, 2026Other Short-term Investments
11.11BINRFY2026 · Mar 31, 2026Accounts Receivable
7.81BINRFY2026 · Mar 31, 2026Inventory
6.83BINRFY2026 · Mar 31, 2026Accounts Payable
3.91BINRFY2026 · Mar 31, 2026Short-term Debt
24.65MINRFY2026 · Mar 31, 2026Other Current Liabilities
330.80MINRFY2026 · Mar 31, 2026Long-term Debt
11.25MINRFY2026 · Mar 31, 2026Other Non-current Liabilities
35.80MINRFY2026 · Mar 31, 2026Common Stock (Book)
160.56MINRFY2026 · Mar 31, 2026Retained Earnings
33.29BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
41.59BINR435.89M · vs all stocks (USD)
52-Week Low
1.64KINRUpdated Jul 20, 202652-Week High
2.53KINRUpdated Jul 20, 202652-Week Change
42.98%vs all stocks
Beta
-0.0180xvs all stocks
50-Day MA
2.25KINRUpdated Jul 20, 2026200-Day MA
1.99KINRUpdated Jul 20, 2026Avg 10-Day Volume
957.96KSharesUpdated Jul 20, 2026Avg 30-Day Volume
486.23KSharesUpdated Jul 20, 2026Diluted EPS (TTM)
44.56INRUpdated Jul 20, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA
Three years of positive free cash flow, with the 50-week average above the 200-week.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
High earnings qualityNotable
Earnings Quality Score: 0.67
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $4.05B, above the global median of $1.15BNotable
Market cap (USD): 4,053,348,036.667Global Median: 1,146,734,693.424
Levered free cash flow is $53.08M, above the global median of $16.24MNotable
Levered free cash flow (USD): 53,078,800.835Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
HLB Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Tier 1ProductionApproval-Gated PipelineRule
China Medical System Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Pharmaceutical Da Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Xuanzhu Biopharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dyne Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Livzon Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Xiamen Amoytop Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
SJS Enterprises Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMulti-Year Revenue, Profit, And Income GrowthThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA
Ajanta Pharma Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMulti-Year Revenue, Profit, And Income GrowthThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA
Thyrocare Technologies Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMulti-Year Revenue, Profit, And Income GrowthThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA